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Abstract
Behçet disease is a chronic relapsing systemic disease with possible life-threatening presentations. Management of this disease can
be challenging and reports of the off-label use of anti-TNFα agents for the treatment of severe manifestations are increasing, with good
results. The authors report a case of Behçet disease with a sudden and severe multi-systemic onset successfully treated with
infliximab.
Case report
A 34-year-old woman presented in our emergency department with a 1-week history of asymptomatic cutaneous lesions and one oral
aphthous ulcer, together with fever and myalgia. She was otherwise healthy and was on no regular medication. There was no history of
infections or drugs before the development of the cutaneous lesions and she denied similar previous episodes.
Figure 1 Figure 2
Figure 1. Clinical features of the sparse cutaneous lesions on the thorax and
abdomen
Figure 2. An erythematous pustule on the right upper back
Figure 3 Figure 4
Figure 3. Erythematous macules and papules on the lower back
Figure 4. Cutaneous lesions on the lower limbs
Physical examination revealed erythematous papules and pustules. 2-8 mm, localized on the
trunk and limbs and one aphthous ulcer on the upper lip, 6 mm in diameter. She was febrile (38°C)
and there were no other findings on physical examination. Giving the systemic presentation, she
was hospitalized for investigation.
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Figure 5. Clinical features of the
aphthous ulcer on the upper lip
Figure 6 Figure 7
Figure 6. Genital ulcer developing 2 days after the patient was hospitalized
Figure 7. Two aphthous ulcers on the tongue, developing during
hospitalization
Figure 8 Figure 9
Figure 8. Erythema nodosum-like lesions on the lower limbs
Figure 9. Highlight of a cutaneous lesion on the thigh
Two days later she developed a painful genital ulcer and 2 new aphthous ulcers on the tongue. The cutaneous lesions on the lower
limbs evolved to erythema nodosum-like nodules. She then developed intense headaches and impaired vision followed by paraparesis,
left facial palsy, and loss of urinary sphincter control. At this point, she recalled having recurrent oral aphthous ulcers for the last 2
years, but had never considered them to be important. Laboratory workup disclosed leukocytosis (17.32 x 10³/µL, normal 4.00-11.00)
with neutrophilia (11.74 x 10³/µL, normal 2.00-7.50) and elevated C reactive protein (144.02 mg/L, normal 0.0-5.0). Serologic and
immunologic studies, blood, and urine cultures were negative.
Figure 10 Figure 11
Figure 10. Histopathologic examination of a skin biopsy from an erythema-
nodosum-like nodules shows a normal epidermis and lymphocytic
vasculitis in the dermis (H&E x4)
Figure 11. Histopathologic features show the coexistence of lymphocytic
vasculitis and mixed panniculitis (H&E x4)
Figure 12 Figure 13
Figure 12. Higher amplification of the same cutaneous lesions (H&E x20)
Figure 13. Inflammatory infiltrate extends to the adnexal structures (H&E
x20)
Histopathologic examination of a skin biopsy from an erythema nodosum-like nodule showed a normal epidermis, lymphocytic
vasculitis in the dermis, and a mixed panniculitis with an inflammatory infiltrate extending to the adnexal structures at the dermo-
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hypodermal junction. Pathergy test was negative. Ophthalmologic examination detected papilledema. Cerebral MRI and lumbar
puncture revealed features of rhombencephalitis. HLA-B51 was positive. Altogether, these findings allowed the diagnosis of Behçet
disease and the patient started a 3-day course of pulse iv methylprednisolone 1g qd, followed by oral prednisone, 1 mg/kg/day,
without any improvement.
Figure 14 Figure 15
Figure 14. Complete resolution of the aphthous ulcer on the upper lip after a
single infusion of infliximab
Figure 15. Clearance of the cutaneous lesions in the thorax and abdomen
with treatment
Figure 16 Figure 17
Figure 16. Resolution of the cutaneous lesions on the back
Figure 17. Complete clearing of the erythema nodosum-like nodules on the
lower limbs after infliximab therapy
For this reason, she started IV infliximab 5 mg/kg every 6 weeks with complete resolution of clinical disease after the first infusion and
without sequelae. The patient remains free of the disease after one year of follow-up, still under infliximab therapy.
Discussion
Behçet disease is a chronic systemic inflammatory disorder of unknown etiology. The exuberant and sudden onset of the multi-
systemic involvement in our patient is uncommon and usually related with a poor prognosis [1, 2]. Along with this severe presentation,
the presence of HLA-B51 and the lack of response to high-dose corticosteroids were also predictive of a worse outcome [1, 2, 3].
Such a dramatic clinical picture requires aggressive immunosuppressive therapy in order to achieve rapid control of the disease and
avoid irreversible damage to vital organs [1, 2, 3]. Anti-TNFα agents have been used in Behçet disease because of a role of TNFα
mediated interactions in its pathogenesis [1, 4]. Among these agents, there is greater information on infliximab; 83 percent of Behçet
disease patients on anti-TNFα agents are receiving infliximab [1-3, 5, 6]. This fact, along with the documented high efficacy rates
(>85%) and the rapid effect after a single infusion make it a good candidate for severe presentations resistant to standard therapies or
for those intolerant to those treatments [1-6]. For these reasons, we started infliximab in our patient and obtained a rapid and
complete response. Since relapses are not uncommon after cessation of the anti-TNFα treatment [1, 2, 3], the patient has been kept
on the same therapeutic regimen, so far without complications after 1 year of follow-up. In summary, there is sufficient scientific
evidence to support the use of infliximab in severe, refractory cases of Behçet disease. At the same time we must keep in mind that
this entity has a chronic course, with successive remissions and relapses, highlighting the importance of a long-term effective and
safe therapy. Because there are no data regarding the efficacy and safety of infliximab in Behcet disease over the long term, future
studies are needed in order to optimize treatment protocols and clarify the role of anti-TNFα agents.
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